Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wolters-kluwer-health/minimizing-resistance-consequences-after-virologic-failure-on-initial-Zf1HfwdPHA
References (45)
-
Conway (2001)
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.AIDS, 15
-
S3
AIDS, 17
-
Johnson (2003)
215Top HIV Med, 11
-
Kempf (2004)
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.J Infect Dis, 189
-
Podzamczer (2002)
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).Antivir Ther, 7
-
(2004)
Baseline genotype as a predictor of virologic failure in patients receiving emtricitabine once daily or stavudine twice daily in combination with didanosine and efavirenz [abstract 672 -
Jiang (2003)
Assessing resistance costs of antiretroviral therapies via measures of future drug options.J Infect Dis, 188
-
Walmsley (2002)
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.N Engl J Med, 346
-
Staszewski (2001)
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial.JAMA, 285
-
(2004)
Treatment emergent mutations for previously naive HIV-infected adults failing ZDV + 3TC + EFZ and ABC + 3TC + EFV [abstract 11 -
(2003)
Transmission of drug resistant HIV-1 in patients with acute and early HIV-1 infection -
Hicks (2004)
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.AIDS, 18
-
Sham (1998)
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.Antimicrob Agents Chemother, 42
-
(2005)
Drug resistance is associated with an increased risk of death in patients first starting HAART [abstract 712 -
and the HIV Drug Resistance ARVDRT/VARHS Surveillance Group. US surveillance of HIV drug resistance at diagnosis using HIV diagnostic sera -
Maguire (2000)
Absence of zidovudine resistance in antiretroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: virological evaluation of the AVANTI 2 and AVANTI 3 studies.AIDS, 14
-
J. Raboud, S. Rae, S. Vella, P. Harrigan, R. Bucciardini, V. Fragola, D. Ricciardulli, J. Montaner (1999)
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.Journal of acquired immune deficiency syndromes, 22 3
-
A. MarioCalvo (2003)
Alternation of antiretroviral drug regimens for HIV infection a randomized, controlled trial. Martínez-Picado J, Negredo E, Ruiz L, Shintani A et al. Ann Intern Med 2003; 139: 81-9.Revista Chilena De Infectologia, 20
-
Squires (2000)
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).AIDS, 14
-
Robbins (2003)
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.N Engl J Med, 349
-
Johnson (2003)
Drug resistance mutations in HIV-1.Top HIV Med, 11
-
Raboud JM, Rae S, Vella S. Meta analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
J Acquir Immune Defic Syndr, 22
-
Grover (2005)
Predictors of death, and response to therapy in patients with multi (three)-class drug resistant (MDR) HIV in the UK.Antivir Ther, 10
-
Podzamczer (2002)
81Antivir Ther, 7
-
Martinez-Picado (2003)
Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.Ann Intern Med, 139
-
Initial therapy with abacavir + lamivudine (ABC = 3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (PI) or stavudine (NRTI): ESS40001 (CLASS) -
Matheron (2003)
163Antivir Ther, 8
-
Lexiva package insert, GlaxoSmithKline -
Bartlett (2001)
Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults.AIDS, 15
-
Eron (2000)
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).AIDS, 14
-
Ferrer (2003)
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.J Infect Dis, 187
-
Montaner (1998)
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.JAMA, 279
-
European guidelines for the clinical management and treatment of HIV-infected adults in Europe.
AIDS, 17
-
Staszewski (1999)
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults.N Engl J Med, 341
-
International AIDS Society-USA drug resistance mutations group -
Gartland (2001)
AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.Antivir Ther, 6
-
Eron (2004)
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.J Infect Dis, 189
-
Gathe (2004)
SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1 infected patients.AIDS, 18
-
Matheron (2003)
Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.Antivir Ther, 8
-
Gartland (2001)
127Antivir Ther, 6
-
Shafer (2003)
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.N Engl J Med, 349
-
Grover (2005)
57Antivir Ther, 10
-
A. Fauci, J. Bartlett, E. Goosby, M. Smith, H. Kaiser, S. Chang, Jean Anderson, R. Armstead, A. Baker, David Barr, S. Bozzette, S. Cox, M. Delaney, F. Gordin, W. Greaves, M. Harrington, J. Henning, M. Hirsch, J. Jacobs, R. Marlink, C. Maxwell, J. Mellors, D. Nash, S. Perryman, R. Schooley, R. Sherer, S. Spector, G. Torres, P. Volberding, B. Brady, E. Daniels, D. Feigal, M. Feinberg, H. Gayle, T. Graydon, J. Kaplan, A. Macher, R. Martin, H. Masur, L. Mofenson, J. Murray, J. O'Neill, L. Perez, R. Riseberg, S. Shekar, S. Stanley, J. Whitescarver (1998)
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000HIV Clinical Trials, 1
-
(2003)
Lack of resistance to boosted 908 confirmed through 48 weeks of therapy in naive subjects -
(2004)
Estimation of selective pressure by lopinavir/ritonavir (LPV/r) vs. nelfinavir (NFV) by examination of terminal-phase pharmacokinetics (PK) at steady-state [abstract 6.1
- Publisher
- Wolters Kluwer Health
- ISSN
- 1525-4135
- eISSN
- 1077-9450
- DOI
- 10.1097/01.qai.0000197070.69859.f3
- Publisher site
- See Article on Publisher Site
Abstract
Downloaded from http://journals.lww.com/jaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/12/2020 CLINICAL SCIENCE Minimizing Resistance Consequences After Virologic Failure on Initial Combination Therapy A Systematic Overview John A. Bartlett, MD,* Jeffrey J. Buda, BA,† Birgitta von Scheele, MSc Pharm, MS,‡ Josephine A. Mauskopf, PhD,† E. Anne Davis, PharmD, MS,§ Robert Elston, PhD,|| Martin S. King, PhD,¶ and E. Randall Lanier, PhD,§ reatment of HIV with combination antiretroviral therapy Objective: To identify optimal first-line therapies based on the rate T (ART) has resulted in a greatly extended life expec- of virologic success (VS) and the preservation of future treatment tancy for persons infected with HIV. After the introduction options in antiretroviral therapy (ART)-naive subjects. of combination ART, AIDS incidence and AIDS-related Design: Systematic overview of genotypic resistance mutations deaths decreased dramatically in the United States and from clinical trials of combination ART. 1,2 Europe. For many persons infected with HIV and on active Methods: Various sources were searched for studies in ART-naive ART, HIV has become a chronic condition rather than a subjects providing virologic response rates and genotypes from fatal disease. subjects with virologic failure. The International AIDS Society-USA Currently, there are many options for initial combi- genotypic resistance guidelines were used to
Journal
JAIDS Journal of Acquired Immune Deficiency Syndromes – Wolters Kluwer Health
Published: Mar 1, 2006